GANX - NASDAQ
Gain Therapeutics, Inc.
$1.88
+4.7%Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
At a Glance
Live SnapshotGain Therapeutics, Inc. Management Team
Dr. Khalid Islam Ph.D.
Chairman & Founder
Compensation
$75,000
Dr. Jonas Hannestad M.D., Ph.D.
Chief Medical Officer
Mr. Gene Mack M.B.A.
President, Chief Executive Officer & Director
Compensation
$535,091
Mr. Gianluca Fuggetta
Senior Vice President of Finance & Principal Financial Officer
Compensation
$228,345
Dr. Joanne Taylor Ph.D.
Senior Vice President of Research
Dr. Terenzio Ignoni Pharm.D.
Senior Vice President of Technical Operations
Gain Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $188K worth of GANX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
105.0K
187.95K
0
0.00
+188K
+$188K
Top Buyers
Islam Khalid
Director
$27K
Nicaise Claude
Director
$27K
Riley Jeffrey Scott
Director
$27K
Richman Eric I
Director
$27K
Hasler Hans Peter
Director
$27K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $188K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
GANX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 24, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 13, 2022 | June 16, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.